While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry ...

Two biotech stocks, Ligand Pharmaceuticals and United Therapeutics, are showing resilient action in Friday's stock market.

The market seems to be falling heavily out of love with the AI stocks, and for good reason: CapEx is rising at a staggering rate, especially among the Mag Seven AI darlings, all while the question ...

XBI has nearly 50 points of upside to reach its previous all-time high, and 2026 biotech industry conditions may help it get ...

The next 10 months might be challenging for this biotech.

However, there is one key reason the stock could still deliver outstanding returns over the long run: Its pipeline could help ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

Legend Biotech Corporation (NASDAQ:LEGN) is one of the best high growth healthcare stocks to buy now. RBC Capital cut the price target on Legend Biotech Corporation (NASDAQ:LEGN) to $62 from $66 on ...